Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Perrigo’s partner files ANDA for generic acne drug
Perrigo Company, a healthcare supplier, has reported that its partner Cobrek Pharmaceuticals has filed an abbreviated new drug application for clindamycin phosphate foam 1%, a generic version of
Perrigo Company, a healthcare supplier, has reported that its partner Cobrek Pharmaceuticals has filed an abbreviated new drug application for clindamycin phosphate foam 1%, a generic version of
Lux Biosciences, a biotechnology company, has completed enrollment in its Phase III Lucida clinical trial program for Lumitect. The Lucida clinical trial program is investigating the one-year use
Yousef Haj-Ahmad, president of Norgen Biotek, said: “We are excited about this OEM manufacturing and supply agreement for our best-in-class RNA isolation kits. Exiqon is well known for
Syneron said that its novel Laser-in-Handpiece concept, incorporated in its LiteTouch Erbium: YAG dental laser, represents a unique combination of superior power and high-speed cutting abilities, along with
Gardiner has served as medical director, global medical affairs & senior medical officer for Bristol-Myers Squibb (BMS) Medical Imaging and vice president, medical sciences for the medical imaging
According to the company, i3Cube replaces the need for multiple systems and applications to manage study activities with an integrated solution that centralizes study information into a single
Emergent BioSolutions, a biopharmaceutical company, has reported that the Phase I/II clinical trial for its anthrax immune globulin therapeutic candidate has commenced with the initial treatment given to
We are excited to enter the China market, which represents a continuation of our efforts to expand our international footprint in key markets where breast-care is increasingly becoming
The two partners will establish a joint research center at Tsinghua University, the Bayer-Tsinghua (Institute of Biomedicine) Research Center of Innovative Drug Discovery. Yigong Shi, a structural biologist,
As one of the first companies to file an abbreviated new drug application containing a paragraph IV certification for this product, Teva has been awarded a 180-day period